Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-05-14

FDA Approved: CAPRELSA — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

The FDA approved a supplemental application for CAPRELSA (vandetanib) submitted by Genzyme Corporation. This action updates the existing NDA, potentially modify…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Caprelsa (vandetanib)

Snippet

SUPPL AP for CAPRELSA (VANDETANIB)